Home / Prepare Your Business for Sale / Physical Therapy Practice

How to Prepare Your Physical Therapy Practice for a Sale or Exit (2026)

Updated April 2026 · CT Acquisitions

Most physical therapy owners decide to sell, hire a broker, and find out 90 days later that their practice is worth 30% to 50% less than they thought. Outpatient PT is one of the most private-equity-consolidated healthcare lanes in the United States: the top 10 outpatient PT operators now control roughly 25% to 35% of the clinic footprint (Provident Healthcare Partners 2025; The Braff Group PT Year in Review 2024 and 2025), up from under 15% a decade ago, and a JAMA Internal Medicine study found PE acquisitions of outpatient PT clinics rose more than 10x from 2010 to 2021 (JAMA Internal Medicine, August 2023). The owners who get top-quartile pricing in this market start preparing 24 to 36 months before they ever talk to a buyer. This guide is the 36-month playbook for what they do.

If you are 6 to 36 months from a possible exit, this is the work that turns a 5x EBITDA outcome into an 8x EBITDA outcome. On a $2M EBITDA outpatient PT practice, that is the difference between a $10M sale and a $16M sale. Whether you want to prepare your physical therapy practice for a sale to private equity, prepare your physical therapy practice for an exit to a strategic acquirer such as Select Medical or U.S. Physical Therapy Inc., or simply maximize value over the next 1 to 3 years before going to market, the work below applies.

What Private Equity Actually Buys in Physical Therapy (2026)

The US physical therapy services market is estimated at $46.3B in 2024, growing to roughly $50.5B in 2025 with a 4% to 5% projected CAGR through 2030 (IBISWorld 2025; Grand View Research 2025). The broader rehab and physical therapy services market is forecast at $74B by 2032 (Verified Market Research 2025). Approximately 38,000 to 40,000 outpatient PT clinics operate in the US, serving more than 230,000 licensed PTs (APTA Workforce Analysis 2024; BLS OES 29-1123, May 2024). Outpatient PT now ranks alongside dental, dermatology, veterinary, and ophthalmology as one of the most PE-active healthcare services categories (Bain Global Healthcare Private Equity Report 2024 and 2025; PwC Health Services Deals Insights 2024 and 2025). The sponsor money flowing in is not random. PE buys specific profiles, and the profile you build determines the multiple you get.

The PE-attractive physical therapy profile

• EBITDA threshold for a platform-quality deal: $1M to $3M is the entry band where sponsor-backed platforms will run a competitive add-on process. Below that, you are an add-on inside a roll-up. Above $5M, you become an attractive bolt-on for the larger platforms. Above $10M, you are a platform candidate yourself.
• Payer mix: Commercial 55% to 70%, workers comp 10% to 20%, Medicare under 20%, Medicaid under 10% is the platform-grade target. Commercial-payer-heavy + sports-medicine + workers-comp practices trade at the top of the band (Provident Healthcare Partners 2024 and 2025; APTA + WebPT 2024 reimbursement benchmarks).
• Geography: Sun Belt (FL, TX, NC, SC, AZ, NV, TN), Mid-Atlantic, the Carolinas, and growth metros in the Mountain West are where 2026 sponsor demand concentrates. Footprints of Upstream Rehabilitation, Ivy Rehab, PT Solutions, Spooner, and Foothills tell you exactly where add-on appetite is strongest.
• Referring-MD concentration: No single referring physician above 15% of new patients. Top 5 below 40%. Concentration above 25% from a single MD triggers a 0.5x to 1.5x multiple haircut or buyer walk (Provident Healthcare Partners 2024 and 2025).
• PT depth: Twelve-month rolling PT retention above 80% is “satisfactory” per industry benchmarks; above 85% is platform-grade (Provident Healthcare Partners 2024; WebPT 2024). National PT vacancy rates run 12% to 18% across outpatient settings (APTA Workforce Analysis 2024; HHS Workforce Reports 2024 and 2025).
• Owner-PT role: Owner-PT delivers under 20% of clinical visits, with a clinical director DPT running clinical operations and a practice administrator running billing and payer relations. Clinical director in place 12+ months pre-sale.

Active physical therapy PE platforms in 2026

The list below covers the most active sponsor-backed PT platforms and public strategic operators in the 2024 to 2026 cycle. This is who will see your teaser. Clinic counts are point-in-time; sources include SEC filings (ATIP, SEM, USPH, Concentra), Genstar Capital press (Spooner, February 2024), Provident Healthcare Partners PT M&A Updates 2024 and 2025, The Braff Group Year in Review 2024 and 2025, PrivSource, PitchBook, and sponsor portfolio pages.

Layer the public strategic acquirers on top of the PE platforms. Select Medical (NYSE: SEM) closes 20 to 30 outpatient tuck-ins per year through its NovaCare Rehabilitation and Select Physical Therapy brands (Select Medical 10-K 2024; Q3 2025 10-Q). US Physical Therapy Inc. (NYSE: USPH) acquired Hands-On Therapy Services for $14.5M cash plus equity rollover in Q1 2024, Northwest Physical Therapy Solutions in Q3 2024, MOTUS Specialists Physical Therapy in Q4 2024, and seven additional partnerships through 2025 (USPH 10-Q filings; USPH Q3 2025 earnings call transcript). The Concentra IPO completed July 25, 2024 with a $397.5M raise and implied EV of roughly $4.5B (Concentra S-1 and 424B4 filings, SEC EDGAR). Encompass Health (NYSE: EHC) participates primarily in inpatient rehab but has selective outpatient PT exposure. Hospital systems and ACOs (HCA, Kaiser, Ascension, select academic medical centers) represent an estimated 5% to 10% of outpatient PT exit pathways and tend to pay below PE-platform multiples (Provident Healthcare Partners 2025; HFMA bundled-payment alignment content).

Physical Therapy Valuation Multiples in 2026 (What You Are Actually Worth)

The multiple a buyer pays comes down to your size, payer mix, referring-MD concentration, owner-PT clinical share, and geographic fit. Here is the 2026 range, cross-referenced from Peak Business Valuation PT 2025 to 2026, Provident Healthcare Partners 2024 to 2025 PT M&A Updates, The Braff Group PT Year in Review 2024 and 2025, Sofer Advisors Medical Practice Valuation Multiples Guide 2025 to 2026, Eton Venture Services PT valuation content, and PitchBook deal records.

SDE multiples (small, owner-operated practices)

EBITDA multiples (PE-attractive size)

IBBA Q4 2025 Market Pulse cross-reference: $1M to $2M lower-middle-market healthcare prints 3.0x to 3.3x and $2M to $5M around 4.1x EBITDA blended (IBBA / M&A Source Q4 2025, PR Newswire, January 2026). The PT-specific premium runs +1.0x to +3.0x above the IBBA blend for PE-attractive practices, driven by referral-volume defensibility and the active PE buyer set documented in Section 1.

Recent disclosed physical therapy transactions (2024 to 2026)

Sources: Genstar Capital press (February 2024); Partners Group portfolio and PitchBook; BDT Capital portfolio; USPH 10-Q Q1 2024, Q3 2024, and 10-K 2024 (SEC EDGAR); Concentra S-1 and 424B4 (SEC EDGAR); Upstream Rehabilitation corporate press; Ivy Rehab corporate press; Waud Capital portfolio.

Most PT add-ons close sub-$10M total deal value, paid in cash plus seller notes plus earn-out plus equity rollover. The USPH partnership model is the most explicit on equity rollover (local PT owners retain 20% to 49% in their group). Platform-tier recapitalizations (Confluent Partners Group, Athletico BDT, PT Solutions Welsh Carson, Upstream Audax) are the reference for what is achievable at scale with full owner-out, clean commercial payer mix, and platform-grade compliance hygiene.

The 14 Value Levers That Move Your Multiple (Ranked by Impact)

These are the levers that move PT multiples in the 24 months before a sale. Each one has a current state, a target state, and an estimated financial impact. Ordering is by dollar impact per unit of effort, synthesized from Provident Healthcare Partners 2024 and 2025, The Braff Group PT Year in Review 2024 and 2025, Sofer Advisors 2025 to 2026, Peak Business Valuation PT 2025 to 2026, APTA and WebPT 2024 reimbursement and operating benchmarks.

Lever 1: Shift payer mix toward commercial and workers comp

Current: Medicare 30%+ of visits, commercial 35% to 45%, workers comp 5% to 10%, Medicaid 10%+. Target: Commercial 55% to 70%, workers comp 10% to 20%, Medicare under 20%, Medicaid under 10%. Impact: Commercial PPO reimbursement averages $100 to $140 per visit vs. Medicare at $80 to $95 and Medicaid at $50 to $70; workers comp averages $150 to $300 per visit (APTA and WebPT 2024 benchmarks). Lifting commercial mix by 15 percentage points on a $5M revenue practice adds roughly $300K to $500K of revenue, with most dropping to EBITDA. At a 7x multiple that is $2M to $3.5M of additional sale price. How: Aggressive commercial in-network credentialing across BCBS, Aetna, Cigna, UnitedHealthcare, Humana; drop poor-pay Medicaid contracts where state law allows; build workers comp panel relationships with third-party administrators and employer occupational health programs; push direct-access cash-pay programs in direct-access states.

Lever 2: Move the owner-PT out of the clinical chair into an operator role

Current: Owner-PT delivers 40%+ of clinical visits, signs every clinical chart, owns most referring-MD relationships, has not taken more than a week off in 5 years. Target: Owner-PT delivers under 20% of clinical visits; clinical director DPT runs clinical operations; practice administrator runs billing, scheduling, and payer relations; owner-PT transitions referring-MD relationships to clinical director over 18 to 24 months. Impact: Owner dependence is the single most cited multiple haircut in PT M&A literature (Provident Healthcare Partners 2024 and 2025; Practice Brokers; The Braff Group). On a $1M to $3M EBITDA practice, eliminating key-person risk moves the multiple from the 5x band into the 6.5x to 7x band, worth $1.5M to $6M of price. How: Clinical director DPT hire 18 to 24 months pre-sale at $110K to $150K plus bonus; practice administrator hire at $75K to $110K plus bonus; document clinical SOPs; build a leadership scorecard; transition referring-MD relationships in person over 12 to 18 months; take a 2-week unplugged vacation as the stress test.

Lever 3: Lift average visits per episode of care (within evidence bounds)

Current: 6 to 8 visits per episode (under-utilization signals). Target: 10 to 14 visits per episode for orthopedic conditions, with sustained evidence-based documentation that supports the visit count. Impact: Lifting average visits per episode by 4 (on say $90 per visit commercial average) adds $360 per episode of care. On 2,000 episodes per year that is $720K of additional revenue, with 50% to 60% dropping to EBITDA at PT gross margins. At a 7x multiple that is $2M to $3M of additional sale price. Important risk: too-high visits per episode (15+) triggers Medicare Targeted Probe and Educate audits. How: Therapist training on functional outcomes measurement (FOTO, OutcomeIQ, Care Connections), evidence-based protocol adoption, documentation training to support medical necessity, careful Medicare KX modifier discipline at the patient level.

Lever 4: Build a cash-pay service line

Current: 100% insurance practice, no cash-pay revenue. Target: 10% to 25% cash-pay revenue from dry needling, cupping, performance training memberships ($99 to $250 per month), post-rehab fitness, sports performance assessments, executive wellness, BFR (blood flow restriction) training. Impact: Cash-pay gross margins run 60%+ vs. 35% to 45% on insurance-only revenue (APTA + WebPT 2024). Adding $500K cash revenue on a $5M practice adds roughly $300K to $400K to EBITDA. At a 7x multiple that is $2M to $3M of additional sale price. The cash-pay line also reduces payer concentration risk in the buyer’s underwriting. How: Stand up a cash-pay LLC or service line; configure Stripe or membership billing; train PTs on cash-program presentation; market through the clinic newsletter and Google; track recurring revenue separately for the CIM.

Lever 5: Diversify the referring-MD base

Current: Top 1 referring MD above 25%; top 3 referring MDs above 50%. Target: Top 1 referring MD below 15%; top 5 below 40%; active referral relationships with 15+ primary care, orthopedic, sports medicine, chiropractic, and post-op physicians. Impact: Top-MD concentration above 25% is the single most cited diligence concern in PT M&A. Above 30% it triggers a 0.5x to 1.5x multiple haircut or buyer walk (Provident Healthcare Partners 2024 and 2025). Moving your top from 30% to 15% on a $2M EBITDA practice is worth $1M to $3M of price. How: Direct-access marketing to consumers in direct-access states, patient self-referral programs, build relationships with 10+ new MD groups, content marketing for primary-care referral capture, sports team and athletic club partnerships, formal sports-medicine pathways.

Lever 6: EMR adoption with clean monthly reporting

Current: Sub-scale EMR or paper, no service-line P&L, KPI tracking anecdotal. Target: WebPT (60%+ outpatient PT market share per WebPT corporate site), Raintree, Net Health TheraOffice, Clinicient Insight, Prompt EMR, or Optima with monthly reporting on visits per PT per day, revenue per visit by payer, denials by payer, AR aging, MIPS performance, and FOTO outcomes. Impact: Estimate +0.5x to 1.0x multiple uplift, driven primarily by data-room speed and KPI defensibility during diligence. Also drives a 5% to 12% revenue lift through reduced denials and better documentation (WebPT customer-success content 2024 and 2025; Net Health 2025). How: Budget $30K to $100K implementation cost plus per-clinician license; force adoption with billing-tied compliance; run a 90-day data-cleanup project before any QoE.

Lever 7: PT retention and clinician depth

Current: 18%+ annual PT turnover, no career ladder, CE budget under industry norms. Target: Annual PT turnover under 12% (APTA target), defined PT career ladder (staff PT, senior PT, clinical specialist, clinic director, regional director), CE allowance, specialty certification support (OCS, SCS, certified hand therapist, dry needling). Impact: Replacement cost of a licensed PT is 50% to 100% of salary including lost productivity during onboarding (APTA Workforce 2024; SHRM healthcare turnover). On a 25-PT practice with 25% turnover, that bleeds $625K to $1.5M annually. Better retention lifts utilization, defends patient continuity, and feeds directly into the diligence narrative on whether your PT base is a defensible asset. How: Competitive base plus visit bonus; paid CE days; sponsor OCS / SCS specialty certification; clinical mentorship program; non-compete that is enforceable in state of operation; non-solicit and patient-relationship clauses that survive even where noncompete fails.

Lever 8: Revenue per visit and pricing discipline

Current: Blended revenue per visit below $95. Target: Blended revenue per visit $110 to $135, driven by payer-mix shift to commercial plus workers comp plus cash-pay, and by appropriate add-on procedures: dry needling 20560, manual therapy 97140, neuromuscular reeducation 97112, therapeutic activities 97530. Impact: A 5-clinic, 10,000-visit-per-year practice that lifts blended revenue per visit by $15 ($95 to $110) adds $150K of revenue with most dropping to EBITDA. At a 7x multiple that is $1M of additional sale price. How: Train staff on 8-Minute Rule mathematics, ensure billing captures appropriate add-on procedures, kill discounting practices that depress revenue per visit, run a quarterly fee-schedule review.

Lever 9: EBITDA add-back hygiene

Current: Owner mixes personal expenses through the business with no documentation; related-party rent at above-FMV; no add-back schedule. Target: Every potential add-back documented as it happens with the underlying invoice or payroll record; related-party rent restruck to FMV with appraisal on file; clean payroll for owner-family members. Impact: Every defensible dollar of adjusted EBITDA gets multiplied. On a 7x multiple, $100K of clean add-backs equals $700K of sale price (Morgan & Westfield QoE guide; Eton Venture Services). How: Adopt a monthly add-back log starting today. Document the business purpose of every charge. Get an FMV rent appraisal if you own the real estate. Common PT add-backs that hold up: owner-PT compensation above market (owner-PT bills clinical visits AND takes $300K salary, but a hired DPT clinical director costs $110K to $135K plus a practice manager at $75K to $95K; the delta adds back), owner spouse or family on payroll, owner vehicle and personal travel, country-club, one-time legal fees (FTC noncompete reviews, wage-hour matters), CE conference cost above $2K to $5K per PT per year, ERC, EMR conversion one-time costs.

Lever 10: Working capital normalization and denial-rate clean-up

Current: AR cycle stretched to 60+ days, denials above 12% of charges, deferred revenue on prepaid programs not isolated. Target: AR cycle 40 to 50 days, denials under 8% of charges, deferred revenue on prepaid memberships and packages separately tracked with a monthly roll-forward. Impact: The working capital peg is set off the trailing 6 to 12 months (most commonly TTM average per BDO and Morgan & Westfield). A volatile AR pattern lets the buyer set a higher peg, which subtracts from purchase price. Estimate: poorly managed working capital can cost 2% to 5% of enterprise value at close. PT-specific risk: high denial rates also imply documentation compliance issues that buyers price in separately. How: Outsource or insource billing with KPI accountability (Net Health, WebPT Billing, Raintree RCM, or third-party shop such as SPS or PT Billing Pro); tighten authorization processes; weekly denial-trend review by payer.

Lever 11: Real estate decision (own or lease, and the sale-leaseback option)

Current: Owner-occupied real estate held in the same entity as the operating business, or in an LLC at above-FMV rent. Target: Real estate in a separate LLC at FMV NNN lease to the operating company, with a clear path for the buyer to either assume the lease or buy the real estate. Impact: Separating real estate often lifts the implied EBITDA multiple on the operating business because the buyer is not forced to underwrite real estate exposure (Plante Moran sale-leaseback primer; Northmarq sale-leaseback guide; W. P. Carey content). A sale-leaseback can convert up to 100% of property market value as cash vs. 70% to 80% LTV via traditional financing. Estimated impact: holding real estate separately at FMV typically adds 0.5x to 1.0x to the operating company multiple. How: Get an FMV market rent study now. Restruck rent. Decide before going to market whether the real estate is part of the deal or held back.

Lever 12: Marketing diversification

Current: 60%+ of patient volume from owner-PT’s personal referring-MD relationships. Target: Under 30% from owner-PT relationships; mix of MD referrals, direct-access self-referrals, content marketing, community partnerships, athletic team sponsorships, paid search, Google Local Service Ads. Impact: Concentrated referral source is key-person risk by another name. Diversified, trackable marketing is what makes the demand engine transferable in the buyer’s underwriting. Estimate +0.25x to 0.75x multiple uplift. How: Branded post-discharge review request flow inside the EMR; LSA and Google Ads under a marketing manager (not the owner-PT); SEO investment 12+ months pre-sale; sports team sponsorship.

Lever 13: Compliance scrub (PT-specific)

Current: PT licenses in clinical staff’s names but no centralized tracking; OIG LEIE not screened; MIPS quality reporting submitted late or sub-target; KX modifier discipline uneven; PTA supervision rules not documented; CQ modifier billing inconsistent. Target: PT licenses, NPIs, PECOS, CAQH, and all panel credentialing tracked in a centralized system; OIG LEIE monthly screening for every clinician and admin (excluded individuals cannot be billed under); MIPS reporting on time with target performance scores above 75 to avoid the 9% downward payment adjustment; KX modifier discipline at the patient level; PTA supervision rules documented and audited state by state; CQ modifier billing at the correct 85% level. Impact: Each of these can kill or re-trade the deal at confirmatory diligence. See the deal-killer section below for specifics. How: Cover this in months 24 to 12 of the run-up, before the QoE.

Lever 14: Orthopedic surgeon and sports medicine adjacency (where Stark / AKS permits)

Current: Loose informal relationships with referring orthopedic surgeons; no written medical-director agreement; no shared protocols. Target: Formal medical-director agreement that is Stark Law and Anti-Kickback Statute compliant, written at FMV, with shared post-op PT pathways and outcomes reporting back to surgeons. Where state law permits and the structure is clean, consider ambulatory surgery center adjacency or co-location. Impact: Formal adjacency to a surgical referral source defends volume in a way buyers underwrite at a premium. Estimate +0.5x to 1.0x multiple where formally structured. How: Healthcare-attorney review of any proposed structure; FMV opinion on medical-director compensation ($150 to $300 per hour typical); written protocols; outcomes reporting back to surgeons; clean documentation that referrals are not tied to compensation.

What PE Asks Before They Send an LOI (The Pre-LOI Diligence Stack)

Before a PE firm commits to a letter of intent, they ask for a focused diligence package. The list below is the real ask from a 2026 PE healthcare-services firm targeting an outpatient PT business. The “why” and “how to prepare” expand each item to what is typical across the industry.

1. Income statements for 2023, 2024, 2025, plus latest trailing twelve months

Why PE asks: They are building the LTM EBITDA they will multiply. They want trend (growth rate, margin trajectory), seasonality (PT volume tends to peak in Q1 after benefit-year reset as commercial patients hit deductibles, with a softer Q4 as patients defer care to next year), and one-time movers. LTM is the bridge between the most recent year-end and today, so the headline price reflects current run-rate, not stale data.

How to prepare: Accrual-basis P&L by month, mapped to a clean chart of accounts. Service-line P&L: PT evaluation (97161, 97162, 97163) vs. therapeutic exercise (97110) vs. manual therapy (97140) vs. neuromuscular reeducation (97112) vs. therapeutic activities (97530) vs. dry needling (20560) vs. cash-pay performance training. Reconcile to tax returns so there are no surprises in confirmatory diligence.

2. Balance sheet at the latest month

Why PE asks: Two reasons. First, to start sizing the working capital peg they will set in the purchase agreement. Second, to identify net debt (cash minus interest-bearing debt minus debt-like items). PT-specific debt-like items include unfulfilled prepaid visit packages, cash deposits for performance training memberships, deferred maintenance on EMR or hardware, capital leases on therapy equipment, and any unfunded PTO accruals for clinical staff. Both peg and net debt come out of the purchase price.

How to prepare: Tie the balance sheet to the trial balance. Isolate deferred revenue from prepaid memberships and packages as a distinct line with a roll-forward schedule. Identify which liabilities are debt-like.

3. Adjusted EBITDA bridge with add-back documentation

Why PE asks: They want a sneak peek at your adjusted EBITDA story before they sink diligence cost into the file. If your add-backs are aggressive or undocumented, they discount the rest of your numbers.

How to prepare: Build the bridge from book EBITDA to adjusted EBITDA, line by line. Document every add-back with the underlying invoice or payroll record. See Lever 9 above for the standard PT add-backs that hold up. Source: Morgan & Westfield QoE guide; Eton Venture Services PT content; Provident Healthcare Partners 2024 to 2025.

4. Anonymized employee roster (titles, start dates, pay structure, licensure)

Why PE asks: They stress-test two risks. First, PT retention. Licensed PTs and PTAs are highly mobile and can take patient relationships and referring-MD relationships with them. National PT vacancy rates run 12% to 18% across outpatient settings (APTA Workforce Analysis 2024; HHS Workforce Reports 2024 and 2025). PE wants to see if your PT base is a defensible asset or a flight risk. Second, owner-PT dependence. If owner-PT generates 40%+ of clinical visits or owns the bulk of referring-MD relationships, key-person risk hits the multiple.

How to prepare: Roster columns: role (DPT, PT, PTA, ATC, OT, OTA, SLP, front desk, billing), hire date, full-time vs. part-time, W-2 vs. 1099 with classification rationale (California AB5 has effectively banned 1099 PTs in California since 2020), comp structure (salary plus visit bonus plus production), state PT license number plus expiration plus status, NPI, malpractice carrier and limits, active non-compete or non-solicit. Calculate 12-month and 24-month rolling PT retention. Above 80% PT retention is satisfactory per industry benchmarks (Provident Healthcare Partners 2024; WebPT 2024). Above 85% is platform-grade.

5. Revenue breakdown by service line, payer, and referral source

Why PE asks: This is the single most diagnostic exhibit in PT. It tells them payer mix (commercial vs. workers comp vs. Medicare vs. Medicaid vs. self-pay), average revenue per visit by payer, average visits per episode of care by payer, referral source concentration, and clinical visit yield per PT.

How to prepare: Pull from WebPT, Raintree, Net Health TheraOffice, Clinicient Insight, Prompt EMR, or Optima. Three columns minimum: revenue by payer category, visit count by payer, average revenue per visit by payer. APTA 2024 industry benchmarks for average outpatient PT revenue per visit: Medicare $80 to $95, commercial PPO $100 to $140, Medicaid $50 to $70, workers comp $150 to $300. Average visits per episode of care: orthopedic 10 to 14, Medicare Part B 6 to 8, workers comp injury 12 to 20 (WebPT State of Rehab 2024; APTA Outcomes Registry).

6. Referring-provider and self-referral roster

Why PE asks: PT referrals concentrate in orthopedic surgeons and primary care MDs in non-direct-access states. Top referring MD concentration above 25% triggers buyer pushback because the relationship can flip post-close if the owner-PT was the personal anchor. Buyers also want to see direct-access patient share in states that allow PT self-referral because direct-access volume is defensible patient-relationship revenue.

How to prepare: Top 20 referring providers table for the last 3 years, with new-patient count and revenue per referring provider. Direct-access patient count and revenue separately. Note any formal medical-director or referral-management contracts and confirm Stark Law and Anti-Kickback Statute compliance.

7. Five-year operating plan

Why PE asks: PE underwrites a forward case (years 1 through 5 post-close). They want to see if you have a credible growth story (de novo clinic builds, additional PT hires, payer-mix shift, cash-pay program ramp, geographic expansion, ortho-group partnership) and how aggressive you are. They will overlay their own model on top, but your plan tells them whether you understand your own levers.

How to prepare: A simple operating model: revenue by clinic, PT FTE ramp, gross margin assumptions, overhead growth, EBITDA. Include capacity build (PTs and clinic capacity), planned expansion territories or service lines, pricing actions, and any commercial pipeline.

8. Equipment, modality, and lease schedule

Why PE asks: Three reasons. CapEx forecast (PT equipment has long useful lives: treadmills 10+ years, ultrasound units 8 to 10 years, e-stim 8 to 10 years, dry needling supplies recurring), so post-close CapEx is light but identifiable. Capital lease vs. owned vs. financed (leased equipment is debt-like and comes out of purchase price). Real estate lease change-of-control language: PT clinic leases frequently have landlord-consent clauses on assignment that surface in confirmatory.

How to prepare: Equipment list with make, model, year, purchase date, ownership status, monthly payment. Lease abstract for every real estate lease with assignment and change-of-control language flagged.

9. Credentialing and insurance panel roster

Why PE asks: PT credentialing transferability is payer-by-payer. In-network commercial credentialing (BCBS, Aetna, Cigna, UnitedHealthcare, Humana), Medicare PECOS enrollment, Medicaid enrollment by state, workers comp panel acceptance, PIP panel acceptance. Each payer has its own change-of-control and assignment requirements that surface at confirmatory.

How to prepare: Roster of every PT and PTA with NPI, PECOS Medicare enrollment status, Medicaid IDs by state, in-network commercial panels with effective dates and renewal dates. CAQH profile completeness for each PT.

10. Compliance files (PT-specific)

Why PE asks: PT has a defined CMS audit profile via Targeted Probe and Educate (TPE), Comprehensive Error Rate Testing (CERT), and KX modifier review. PE wants to see audit history (any TPE rounds in the last 5 years), MIPS quality reporting history (PT MIPS exposure with 9% upward and 9% downward payment adjustments by performance year per CMS QPP), and any OIG investigations or DOJ Civil False Claims Act activity in the PT sector.

How to prepare: 5-year history of any Medicare audits or recoupments, current MIPS performance scores and submissions across the PI, IA, Cost, and Quality categories, OIG LEIE screening on every clinical and admin staff member (no LEIE-excluded individual can be billed under), and a written compliance program document.

Confirmatory Diligence (After You Sign the LOI)

Once an LOI is signed and exclusivity starts (typically 45 to 90 days per Colonnade Advisors podcast 020), the buyer runs parallel workstreams. This is the depth of inspection your business will undergo. If anything was hiding, it surfaces here.

1. Quality of Earnings (QoE). Outside accounting firm runs revenue cut-off testing on visits delivered vs. billed vs. collected, payer-specific denial trend analysis, deferred revenue analysis on prepaid memberships and packages, expense normalization, add-back validation, working capital trends. Healthcare-specific QoE pricing runs $50K to $100K typical for $1M to $5M EBITDA PT (SovDoc Healthcare QoE Analysis 2025; Eton Venture Services QoE Cost guide 2025; Coker Group QoE practice content; ARC Healthcare Compliance). Output: an adjusted EBITDA number the buyer locks into the model.
2. Payer and referral concentration plus commercial DD. Payer-by-payer revenue analysis, denied-claim review, in-network contract assignment language, top-referring-provider phone calls (under buyer / advisor cover, not direct), Stark Law and Anti-Kickback Statute scrub on any referral arrangement.
3. IT systems audit. WebPT, Raintree, Net Health, Clinicient, Prompt EMR, or Optima data quality, integration capability with the platform stack, HIPAA security risk assessment, backup and disaster recovery. PE platforms typically want acquired clinics on the same EMR as the rest of the portfolio, and WebPT is the de facto standard in outpatient PT (60%+ market share per WebPT corporate site).
4. Legal. Entity good standing in every state, PT licenses, NPIs, malpractice insurance history, contracts assignment, IP, litigation history (active and threatened, especially patient malpractice claims and wage-hour claims).
5. Compliance and regulatory. Medicare PECOS status, OIG LEIE exclusion screening on every clinician and admin, KX modifier compliance and threshold tracking, GP modifier compliance on PT-delivered care, MPPR (Multiple Procedure Payment Reduction) compliance, Medicare 8-Minute Rule documentation sufficiency, ABN (Advance Beneficiary Notice) file completeness, MIPS quality reporting compliance, PTA supervision compliance state by state, Stark Law and Anti-Kickback Statute scrub on any MD-PT referral arrangement (especially In-Office Ancillary Services Exception structures), state CPOM (Corporate Practice of Medicine) compliance.
6. HR and payroll. W-2 vs. 1099 classification audit (PT 1099 arrangements are common but problematic post-California AB5), I-9 compliance, wage-and-hour exposure (especially overtime classification for PTAs and ATCs), benefits, PTO accrual, non-compete enforceability state by state (FTC noncompete rule vacated September 5, 2025 by the Fifth Circuit per FTC press release; state law controls).
7. Real estate and tax. Lease assignment language on every clinic, landlord consents, ADA compliance for clinic spaces, parking, signage rights. Tax workstream covers federal income, payroll, sales tax (PT services are generally not sales-taxable, but cash-pay performance training and supplement sales may be), property, and business privilege.

Why You Should Pay for Your Own Quality of Earnings Before Going to Market

A sell-side QoE is your own outside accountant’s QoE, paid for by you, before going to market. It does three things: pre-empts the buyer’s QoE by getting to the adjusted EBITDA number first with documentation; surfaces PT-specific issues (deferred revenue on prepaid memberships, denial-trend analysis by payer, KX modifier compliance, MIPS reporting compliance) that you can fix before the buyer sees them; tightens the EBITDA number you take to market, which directly drives the headline price.

Cost

• $40K to $60K for QoE if revenue is below $10M (Eton Venture Services 2025; Morgan & Westfield QoE guide; SovDoc Healthcare QoE 2025).
• $50K to $100K typical range for sell-side QoE on a healthy multi-clinic PT with multiple payer types and a complex referral base (Kahn Litwin Renza buy-side vs. sell-side QoE 2025; Coker Group QoE practice content).
• $150K to $200K for businesses with complex add-backs, multiple entities, MSO structures, or messy books (Eton 2025; ARC Healthcare Compliance).

ROI

Example commonly cited across QoE provider content: $25M revenue PT business, $4M EBITDA. Moving the multiple from 6x to 7x equals $4M of additional sale price. A $75K QoE investment that supports the 1x lift is a 53x return (Eton 2025; SovDoc 2025; Coker). A PT-specific example cited in Provident Healthcare Partners 2024 content: owner reported $1.5M EBITDA on tax returns; the QoE adjusted the number to $1.85M after defensible add-backs (owner-PT compensation re-leveling, family-member payroll removal, one-time legal fees). A separate multi-clinic PT example: $3M reported EBITDA had $400K of revenue recognition issues on prepaid performance memberships and was adjusted to $2.6M after QoE; pre-empting that finding before going to market saved a re-trade scenario at confirmatory.

Deal-Killers That Re-Trade Physical Therapy Transactions (Avoid These)

These are the recurring kill-shots cited across PT M&A advisory content and confirmatory diligence checklists. Most are fixable in 12 to 24 months. None are fixable in 30 days.

1. Referring-MD concentration above 25%

Top referring physician above 25% gets PE nervous; above 30% they price the discount; above 30% to 40% they walk or restructure (Provident Healthcare Partners 2024 and 2025; The Braff Group 2025). The relationship is presumed to flip post-close if the owner-PT was the personal anchor. Mitigation is an 18 to 24 month relationship-transition program to the clinical director DPT.

2. Owner-PT clinical concentration

If the owner-PT generates 40%+ of clinical visits, the entire patient base is presumed at flight risk in a change of ownership. Buyers either price in a 1.0x to 2.0x multiple haircut, structure a multi-year earn-out with clinical-volume hurdle, or require the owner to stay clinical 3+ years post-close. Mitigation: hire and ramp staff PTs over 24 months; owner steps off the schedule 12+ months pre-sale.

3. State Corporate Practice of Medicine violations

Some states (California, Texas, Michigan, Illinois, New York, others) restrict who can own a healthcare practice. Texas, for example, requires PT practices to be PT-owned or MSO-managed with a friendly-PC structure. CPOM violations are confirmatory deal-killers because the buyer’s healthcare counsel will not close on a non-compliant structure. Mitigation: pre-sale CPOM compliance review by healthcare counsel; restructure into MSO plus friendly-PC if needed before going to market (Holland & Knight CPOM state survey; Polsinelli CPOM guidance).

4. Stark Law and Anti-Kickback Statute exposure on physician referral arrangements

If any of your referring orthopedic surgeons received free services, discounted rent, or above-FMV medical-director compensation, that creates Stark Law and Anti-Kickback Statute exposure. Same risk applies if your practice is physician-owned under an In-Office Ancillary Services Exception structure, which CMS continues to narrow. Buyer’s healthcare counsel will surface this at confirmatory. Mitigation: pre-sale Stark / AKS scrub by healthcare attorney; written FMV medical-director agreements; document referral patterns to show no nexus between referrals and compensation (Polsinelli AKS / Stark guidance; APTA Stark Law resources).

5. CMS Targeted Probe and Educate (TPE) audit history

PT practices with prior TPE rounds, especially round 2 or round 3, are flagged as high-risk by buyers. Common TPE findings: insufficient documentation of medical necessity, KX modifier overuse, MPPR errors, plan-of-care signature delays. Mitigation: full chart audit pre-sale; remediate documentation; resolve any open TPE findings before go-to-market (CMS TPE program guidance; APTA TPE resources).

6. KX modifier and Medicare PT threshold compliance

Medicare’s annual PT/SLP combined therapy threshold (indexed annually; $2,330 in 2024 per CMS) requires the KX modifier above the threshold to attest medical necessity. Practices that overuse KX (above 40% of Medicare patients per practice analytics) get flagged for audit. Practices that underuse it (capping every Medicare patient at threshold) lose revenue. Buyer’s QoE and compliance review will surface either pattern. Mitigation: KX modifier audit pre-sale; clean up documentation to support KX where appropriate; train staff on the threshold mathematics (CMS Medicare PT cap guidance; APTA KX modifier resources).

7. PTA supervision and CQ modifier compliance

CMS changed PTA supervision rules effective January 2022 to general supervision in private practice, and required that PTA-furnished services be billed with the CQ modifier at 85% of the physician fee schedule. State PT practice acts vary on PTA supervision (direct vs. general). Mismatch between state law, CMS rule, and clinic practice surfaces in confirmatory and triggers recoupment exposure. Mitigation: confirm PTA supervision compliance in every state of operation; CQ modifier billing audit (CMS PTA supervision guidance; APTA state-by-state supervision survey).

8. MIPS quality reporting non-compliance

PTs are MIPS-eligible clinicians under the Medicare Quality Payment Program, with 9% upward and 9% downward payment adjustments by performance year. Practices that fail to report MIPS take the 9% downward adjustment on Medicare Part B PT revenue. A history of MIPS non-reporting or sub-target performance scores is a buyer red flag because it depresses normalized Medicare revenue and signals compliance immaturity. Mitigation: confirm MIPS reporting status, target a final score above 75 to avoid the downward adjustment, integrate quality-measure capture into the EMR workflow (CMS QPP PT pages; APTA MIPS resources).

9. PT noncompete enforceability after the FTC rule was vacated

The FTC noncompete rule was vacated September 5, 2025 by the Fifth Circuit, so state law controls. California, Minnesota, Oklahoma, and North Dakota ban or heavily restrict noncompetes. Other states (Massachusetts, Illinois, Washington, Colorado, Maine, Virginia) impose income or notice requirements. Buyer’s HR DD will surface whether your PT noncompetes are enforceable in the state of operation. Mitigation: state-by-state noncompete review; rewrite agreements where needed; supplement with non-solicit and patient-relationship clauses that survive even where the noncompete fails (FTC press release 9/5/2025; Seyfarth Shaw noncompete state survey 2025).

10. W-2 vs. 1099 misclassification (California AB5 high risk)

PT practices that run staff PTs or PTAs as 1099 to dodge payroll tax are sitting on a liability. California AB5 has effectively banned 1099 PTs in California since 2020 (no Borello or ABC test exemption for PTs). IRS settlements range $10K to $100K+ per misclassified worker once back taxes, penalties, interest, and legal cost are aggregated (Tax1099 guide; ADP SPARK 2023; IRIS 2025). DOL and IRS renewed enforcement focus in 2025. Any single SS-8 filing by a former contractor opens a workforce-wide audit. Mitigation: W-2 / 1099 audit pre-sale; reclassify if needed; document classification rationale (California Department of Industrial Relations AB5 guidance; IRS Worker Classification 101; ADP SPARK).

11. OIG LEIE excluded individuals on payroll

If any clinical or admin staff member is on the OIG List of Excluded Individuals and Entities, every Medicare claim ever billed under their NPI or for their services is recoupable. Confirmatory HR DD includes a monthly LEIE check on every staff member. Mitigation: monthly LEIE screening as a standing practice; remove any excluded individual on discovery; document the screening process (HHS-OIG LEIE guidance; HHS-OIG compliance resources).

12. State Medicaid PT visit limits and prior authorization friction

Many state Medicaid programs cap PT visits per year (a 30-visit-per-year cap is common; some states impose per-condition limits) and require prior authorization for additional visits. Practices over-billing Medicaid or skipping prior auth steps create recoupment exposure. Mitigation: state-by-state Medicaid PT rules review; tighten the prior-auth workflow; consider exiting low-margin Medicaid contracts before sale (state Medicaid manuals; APTA state Medicaid policy tracker).

13. Workers comp lien aging and personal-injury lien exposure

Some PT practices serve workers comp and PI cases on lien (no upfront pay; payment on case settlement). Lien receivables aged 12+ months are commonly written down 30% to 70% in confirmatory QoE. Mitigation: track lien receivables separately on the balance sheet; reserve aggressively; reduce reliance on lien-based revenue 18 to 24 months pre-sale.

14. EMR data quality issues

If your EMR data is dirty (incomplete plans of care, missing PT signatures, late documentation, no FOTO outcomes captured), the buyer’s IT diligence surfaces it and integration risk gets priced in. Mitigation: 90-day pre-sale EMR data-hygiene project; complete plans of care; reconcile billed visits to EMR-documented visits.

15. Lease assignment and landlord-consent friction

PT clinic real estate leases frequently have landlord-consent or change-of-control clauses that block assignment. Certificate of Need (CON) laws apply to PT in select states for new clinic builds (less common than for ASC or hospital, but worth confirming). Mitigation: lease abstract for every clinic with assignment language flagged; pre-negotiate landlord consents 60 to 90 days pre-LOI (Polsinelli healthcare real estate lease assignment guidance).

The 36-Month Exit Prep Timeline

T-36 months: Cleanup phase

• Switch to accrual basis if still on cash basis
• Pick an EMR (WebPT, Raintree, Net Health TheraOffice, Clinicient Insight, Prompt EMR, or Optima) and migrate; budget $30K to $100K plus per-clinician license
• Start tagging every potential EBITDA add-back as it happens
• Conduct W-2 / 1099 audit; reclassify if needed (especially in California)
• Restruck related-party rent to FMV with appraisal
• Build the org chart; identify clinical director DPT hire and practice administrator hire
• State CPOM compliance review by healthcare counsel
• Stark / AKS scrub on any MD referral arrangement
• OIG LEIE monthly screening process started
• Sales/use tax compliance review by outside counsel where cash-pay or supplement sales apply

T-24 months: Financial discipline and KPI infrastructure

• Clinical director DPT onboarded and starting to take clinical load
• Practice administrator hired and running billing, scheduling, payer relations
• Monthly close in 15 days; payer-mix P&L every month
• KPI dashboard: visits per PT per day, revenue per visit by payer, denial rate by payer, MIPS performance, FOTO outcomes, AR aging
• Launch cash-pay program if not in place; target 10% to 25% cash-pay revenue mix over 18 months
• Payer mix shift: aggressive commercial in-network credentialing across BCBS, Aetna, Cigna, UnitedHealthcare, Humana; drop low-margin Medicaid contracts where state law allows
• Begin diversification of referring-MD base if top MD is above 25%
• Document SOPs for every operational role
• Build the add-back bridge as a living document
• KX modifier audit and clean up Medicare documentation
• PTA supervision compliance audit by state; confirm CQ modifier billing

T-12 months: QoE-ready close discipline, eliminate owner dependence

• Owner-PT steps off the clinical schedule entirely or down to under 20% of visits; clinical director runs clinical operations
• Owner takes a 2-week unplugged vacation as the stress test
• Run the sell-side QoE (budget $50K to $100K)
• Tighten balance sheet: clean AR, kill dormant inventory, isolate deferred revenue on prepaid programs
• Final org-chart review; backfill any gaps
• Final compliance scrub (license transferability, OIG LEIE, MIPS reporting, KX modifier, PTA supervision, CPOM, Stark / AKS)
• Lock in 12 months of clean payer-mix P&L for the CIM
• Lease assignment review with healthcare real estate counsel

T-6 months: Pre-marketing prep

• Engage M&A advisor (sell-side investment bank or healthcare M&A advisor specializing in outpatient PT: Provident Healthcare Partners, The Braff Group, Coker Group, VERTESS, Cain Brothers, Hammond Hanlon Camp, Kaufman Hall, CT Acquisitions). Typical fee structure: $25K to $100K monthly retainer credited against a success fee of 3% to 6% of enterprise value, with Lehman or modified Lehman scaling
• CIM drafted from the QoE and operating model
• Teaser drafted (anonymized 1-pager)
• Buyer list finalized using the Section 1 platform list: Upstream Rehabilitation, Ivy Rehab, PT Solutions, Athletico, Select Medical, USPH, Confluent Health, CORA, Spooner, FYZICAL, Empower, Continental, Bay State, Therapeutic Associates, Foothills, Apex, Twin Boro, H2 Health, plus regional PE platforms. That is 25+ named buyers from Section 1 alone
• Virtual data room populated with everything from the pre-LOI and confirmatory sections above
• Management presentation deck built and rehearsed

T-3 months: Go to market

• Teaser distributed; NDAs collected; CIMs distributed to qualified buyers
• IOIs collected 2 to 3 weeks after CIM goes out
• Narrow to 4 to 6 finalists for management meetings
• Management meetings; LOIs solicited
• Select LOI; sign with exclusivity (typically 45 to 90 days)
• Enter confirmatory diligence; close

End-to-end from engagement to close: 9 to 12 months in a well-run process (Provident Healthcare Partners sell-side timeline 2024; The Braff Group sell-side guide; Wall Street Prep sell-side primer; Auxo Capital Advisors sell-side process guide 2025).

Frequently Asked Questions

How long should I plan for before selling my physical therapy practice to a private equity buyer?

The owners who get top-quartile pricing start preparing 24 to 36 months before going to market. The minimum useful prep window is 12 months because most of the high-leverage levers (shifting payer mix toward commercial, installing a clinical director DPT, getting on a real EMR, running a sell-side QoE) need 12+ months of clean trailing-twelve-months data to be credible to a buyer. Owners who try to sell in under 6 months typically leave 15% to 30% of enterprise value on the table.

What is a realistic EBITDA multiple for a $2M EBITDA physical therapy practice in 2026?

For an outpatient PT practice at $2M EBITDA in 2026, the range is 5.0x to 7.0x EBITDA at the multi-clinic small-end and 6.0x to 9.0x EBITDA for a $2M to $5M regional operator with the owner-out path defined (Provident Healthcare Partners 2024 and 2025; The Braff Group PT Year in Review 2024 and 2025; Sofer Advisors 2025 to 2026). The bottom of the range applies to practices with Medicare-heavy payer mix, owner-PT clinical concentration above 40%, and a top referring MD above 25%. The top applies to practices with commercial payer mix above 55%, owner-PT under 20% clinical share, top MD under 15%, and a clinical director DPT in place. The 36-month prep playbook moves you from the bottom of the band to the top.

Should I get a quality of earnings report done before going to market?

For PT practices at $1M+ EBITDA, yes. A sell-side QoE costs $50K to $100K typical, up to $150K to $200K for complex add-back situations (Eton Venture Services 2025; SovDoc Healthcare QoE 2025). The ROI is leverage. If your QoE supports a 1x multiple uplift on a $4M EBITDA business at a 6x baseline, that is $4M of additional sale price for a $75K investment. More importantly, a pre-market QoE surfaces PT-specific issues (deferred revenue on prepaid memberships, denial-trend analysis, KX modifier compliance, MIPS reporting) while you can still fix them, rather than during exclusivity when the buyer re-trades the deal.

What payer mix do PE buyers want to see in a physical therapy practice acquisition?

The platform-grade target is commercial 55% to 70% of visits, workers comp 10% to 20%, Medicare under 20%, Medicaid under 10%. Commercial PPO reimbursement runs $100 to $140 per visit vs. Medicare at $80 to $95 and Medicaid at $50 to $70; workers comp runs $150 to $300 per visit (APTA and WebPT 2024 benchmarks). Commercial-heavy practices trade at a +1.0x to +3.0x premium over Medicare-heavy practices because the revenue per visit is higher, the denial profile is cleaner, and the regulatory exposure (KX modifier, MIPS, TPE audits, PT cap) is meaningfully lower. Workers comp adds another 0.5x premium because per-visit reimbursement is the highest in the market.

Do I need to put a clinical director DPT in place before I sell?

If your goal is to maximize price, yes, ideally 12+ months pre-sale and 18 to 24 months in role before going to market. Owner-PT dependence is the single most cited multiple haircut in PT M&A literature (Provident Healthcare Partners 2024 and 2025; Practice Brokers; The Braff Group). On a $1M to $3M EBITDA practice, eliminating key-person risk moves the multiple from the 5x band into the 6.5x to 7x band, worth $1.5M to $6M of price. A clinical director DPT hire runs $110K to $150K plus bonus, plus a practice administrator at $75K to $110K plus bonus, and needs 12 to 18 months to fully take clinical load and transition referring-MD relationships before the buyer’s diligence team will believe the transition.

How concentrated can my orthopedic surgeon referral base be before it kills the deal?

Top referring MD concentration above 25% triggers buyer pushback. Above 30% triggers a 0.5x to 1.5x multiple haircut or a walk (Provident Healthcare Partners 2024 and 2025). The buyer’s underwriting assumes the relationship can flip post-close if the owner-PT was the personal anchor, especially in non-direct-access states where the patient flow depends on the MD’s referral pad. The fix is a deliberate 18 to 24 month transition: the clinical director DPT takes the relationship over via in-person visits, shared post-op protocols, outcomes reporting back to the surgeon, and a written medical-director agreement at FMV where the structure supports one (Stark Law and Anti-Kickback Statute compliant). Done right, a 30% top MD relationship can be re-anchored to the clinic before sale instead of evaporating after sale.

What to Do Next

The outpatient PT owners who get top-quartile multiples all do the same three things. They start preparing 24 to 36 months before they want to be out. They put a clinical director DPT in place 12+ months pre-sale and step off the clinical schedule. And they invest in a sell-side QoE before any buyer sees a CIM.

If you are 12+ months from a potential exit and want a structured pre-sale optimization roadmap, CT Acquisitions has healthcare-services operations specialists in our partner network who run multi-quarter prep engagements for outpatient PT. If you are 6 to 12 months out and ready to start the sell-side process, our M&A advisory team runs the buyer outreach against the 25+ active PT platforms named in Section 1. Buyers pay our fee, not you. Either way, the first 30 minutes are free.

The work to prepare your physical therapy practice for an exit is the same work that runs a better practice in the meantime. Better payer mix, lower owner-PT clinical share, cleaner compliance, tighter EMR data, a diversified referral base, and a clinical director DPT taking real clinical load: those are not just buyer-facing levers. They are the things that make the next 24 months of operating the practice less stressful, more profitable, and more sellable when you decide it is time.